Huntington's Disease Society of America
- Our Mission
- HDSA Goals - Mission in Action
- Find your local HDSA Chapter, Affiliate or Regional Office
- Staff directory
- Financials
- Board of Trustees
- Careers
- Faces of HD
-
News & Announcements Archive
- Taryn Reneau Creates "Cure" A Song for HD Families
- Bike for the Cure 2012
- Make a Difference During Huntington's Disease Awarness Month
- Alnylam Committed to HD Therapy Program
- HDYO Launch
- Pacin Parson
- Chase Community Giving Program
- Gillibrand
- Walking the Walk for Research
- hockeynews
- hayden-wins-gairdner-wightman
- Plains to Lake
- Lundbeck Phase I LuAF11167
- HDCRS 2012 SAVE THE DATE
- SSA Announces Addition of Adult Onset Huntington's Disease to Compassionate Allowance List
- NY Marathon Cancelled -- But HDSA Runners Resolve Unbroken
- New Facility with 30+ HD Beds Opens
- SSA Adds Adult-Onset HD to the Compassionate Allowance List
- Tangerine Tango -- Featuring an HD Story
- IRA Charitable Rollover Reinstated
- In Memoriam- Eva Weissman
- HDSA Research Symposium
- HD and HDSA In The News
- Thank You Thursday
In light of Friday's announcement that Alnylam was reducing its work force we inquired about the effect this would have on their ongoing development of a potential therapy for HD in collaboration with Medtronic and CHDI and received the following response.
“Alnylam, in collaboration with Medtronic and CHDI, remains committed to advancing our novel therapy towards the clinic for the treatment of Huntington’s disease,” said Barry Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals. “We believe our pre-clinical data provide a strong rationale for continued advancement of this program, and we are encouraged by the potential that ALN-HTT may offer to Huntington’s patients.”